Bloomios (Bloomios) Days Sales Outstanding : 43.02 (As of Sep. 2023)

View and export this data going back to 2003. Start your Free Trial

What is Bloomios Days Sales Outstanding?

Bloomios's average Accounts Receivable for the three months ended in Sep. 2023 was $0.32 Mil. Bloomios's Revenue for the three months ended in Sep. 2023 was $0.68 Mil. Hence, Bloomios's Days Sales Outstanding for the three months ended in Sep. 2023 was 43.02.

The historical rank and industry rank for Bloomios's Days Sales Outstanding or its related term are showing as below:

BLMS' s Days Sales Outstanding Range Over the Past 10 Years
Min: 2.41 Med: 9.95 Max: 17.48
Current: 16.07

During the past 10 years, Bloomios's highest Days Sales Outstanding was 17.48. The lowest was 2.41. And the median was 9.95.

BLMS's Days Sales Outstanding is ranked better than
94.09% of 998 companies
in the Drug Manufacturers industry
Industry Median: 71.84 vs BLMS: 16.07

Bloomios's Days Sales Outstanding increased from Sep. 2022 (5.64) to Sep. 2023 (43.02).

Bloomios Days Sales Outstanding Historical Data

The historical data trend for Bloomios's Days Sales Outstanding can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bloomios Days Sales Outstanding Chart

Bloomios Annual Data

Trend

Jun02

Jun03

Jun04

Jan05

Jan06

Jan07

Jan19

Jan20

Dec21

Dec22

Days Sales Outstanding

Get a 7-Day Free Trial

2.41

17.48

Bloomios Quarterly Data
	Oct18	Jan19	Apr19	Jul19	Oct19	Jan20	Apr20	Jul20	Oct20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
Days Sales Outstanding	Get a 7-Day Free Trial															5.64	13.08	18.00	14.68	43.02

Competitive Comparison of Bloomios's Days Sales Outstanding

For the Drug Manufacturers - Specialty & Generic subindustry, Bloomios's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Bloomios's Days Sales Outstanding Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Bloomios's Days Sales Outstanding distribution charts can be found below:

* The bar in red indicates where Bloomios's Days Sales Outstanding falls into.

Bloomios Days Sales Outstanding Calculation

Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Accounts Receivable can be measured by Days Sales Outstanding.

Bloomios's Days Sales Outstanding for the fiscal year that ended in Dec. 2022 is calculated as

	Days Sales Outstanding (A: Dec. 2022 )
=	Average Accounts Receivable					/	Revenue	*	Days in Period
=	( (Accounts Receivable (A: Dec. 2021 )	+	Accounts Receivable (A: Dec. 2022 ))	/	count )	/	Revenue (A: Dec. 2022 )	*	Days in Period
=	( (0.056	+	0.526)	/	2 )	/	6.077	*	365
=	0.291					/	6.077	*	365
=	17.48

Bloomios's Days Sales Outstanding for the quarter that ended in Sep. 2023 is calculated as:

	Days Sales Outstanding (Q: Sep. 2023 )
=	Average Accounts Receivable					/	Revenue	*	Days in Period
=	( (Accounts Receivable (A: Jun. 2023 )	+	Accounts Receivable (A: Sep. 2023 ))	/	count )	/	Revenue (A: Sep. 2023 )	*	Days in Period
=	( (0.299	+	0.344)	/	2 )	/	0.682	*	365 / 4
=	0.3215					/	0.682	*	365 / 4
=	43.02

Bloomios (OTCPK:BLMS) Days Sales Outstanding Explanation

For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.

Bloomios Days Sales Outstanding Related Terms

Thank you for viewing the detailed overview of Bloomios's Days Sales Outstanding provided by GuruFocus.com. Please click on the following links to see related term pages.

Bloomios (Bloomios) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Bloomios Inc (OTCPK:BLMS) » Definitions » Days Sales Outstanding

Comparable Companies

Traded in Other Exchanges

N/A

Address

701 Anacapa Street, Suite C, Santa Barbara, CA, USA, 93101

Website

https://www.bloomios.com

Bloomios Inc manufactures, markets, and distributes U.S. hemp-derived supplements and cosmetic products through wholesale distribution channels in the United States of America. It offers its private-label and white-label customers large collections of customizable hemp products that include over 80 products across 7 categories in addition to custom formulation and manufacturing services. Its product categories include edibles, tinctures, oils, salves, capsules, balms, lotions, creams, beverages, and pet treats.

Executives

Douglas S Rohrer	officer: Chief Business Officer	701 ANACAPA, SUITE C, SANTA BARBARA CA 93101
Emc2 Capital Llc	10 percent owner	201 W MONTECITO STREET, SANTA BARBARA CA 93101
Barrett Evans	director, 10 percent owner, officer: Pres, Chief Strategy Officer
Aline Hayuta Elkayam	10 percent owner	104 CHELSEA PLACE, ORMOND BEACH FL 32174
Bibi Daprile	10 percent owner	12 WINDING CREEK WAY, ORMOND BEACH FL 32174
Agpl Acquisition, Inc	10 percent owner	201 W MONTECITO ST., SANTA BARBARA CA 93101
Mammoth Crest Capital Llc	10 percent owner	1712 PIONEER AVE, SUITE 558, CHEYENNE WY 82001
Michael Hill	director, 10 percent owner, officer: Chief Executive Officer	201 WEST MONTECITO STREET, SANTA BARBARA CA 93101
Bryan Glass	director, 10 percent owner, officer: President and Director	20 WEST PARK AVENUE, SUITE 207, LONG BEACH NY 11561
Douglas Boyd	director, officer: Chairman of the Board	8101 TIARA COVE CIR, LAS VEGAS NV 89128
Peter A Hogendoorn	director, officer: President & CEO	13288 AMBLE GREEN PLACE, SURREY A1 V4A 6P5
Harold C Moll	director, 10 percent owner
Van Laare Derek R	officer: Secretary	6119 GORDON AVENUE, BURNABY A1 V5E 3M2
Carlo Civelli	other: former director/officer/owner	111 SOMERSET ROAD, TRIPLE ONE SOMERSET 06-06, SINGAPORE U0 238164
Logan Anderson	director, officer: President & Treasurer	15 HILL CRESCENT, PEMBROKE BERMUDA D8 00000